Rituximab composition of matter patent expired us 2016 eu 2013?

Roughly, yes, but there are caveats.

- United States: The core Rituximab “composition of matter” patent (the basic antibody patent) generally expired around 2016, after accounting for term adjustments.
- European Union: The corresponding EU/EP composition-of-matter patent for Rituximab is commonly cited as expiring around 2013, though exact dates can vary by country and by any term extensions or supplementary protection certificates (SPCs).

Important caveats:
- Patent term is not always a single expiration date in practice. US patents can have term adjustments that push the expiry later, and EU patents can be extended by SPCs in some cases.
- Even after the COF (composition of matter) patent expires, there may be other active patents covering Rituximab (manufacturing processes, formulations, specific uses, hybrids, biosimilars, etc.). These can affect freedom-to-operate.
- Data exclusivity and market exclusivity rules for biologics can also delay entry of competitors in some jurisdictions.

If you’d like, I can look up the exact patent family and give you precise expiration dates by country, with the relevant patent numbers. Just say the word and I’ll pull the details.